Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Ocular Therapeutix (OCUL) Successfully Appeals Patent Case Against Mati Therapeutics, Inc
November 9, 2021 6:26 AM EST
JMP Securities analyst Jonathan Wolleben raised the price target on Ocular Therapeutix (NASDAQ: OCUL) to $30.00 (from $27.00) while maintaining a Market Outperform rating.... More
November 8, 2021 4:34 PM EST
Ocular Therapeutix (NASDAQ: OCUL) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.15 million versus the consensus estimate of $12.45 million.
For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.
...
More
November 5, 2021 9:01 AM EDT
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the Centers for Medicare and Medicaid Services (CMS) released its final rules for the Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) for 2022.
The OPPS final rule confirms that DEXTENZA will continue to be... More
